Milestone Pharmaceuticals Inc. develops and commercializes cardiovascular medicines, centered on CARDAMYST (etripamil) nasal spray. CARDAMYST is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia, or PSVT, to sinus rhythm in adults. Etripamil is also being developed for symptomatic episodic attacks associated with AFib-RVR.
Company news commonly covers CARDAMYST commercialization, payer formulary access, real-world evidence work such as the RESET-PSVT registry, cardiovascular conference presentations, regulatory updates, financial results and business updates. Milestone also reports equity inducement grants and other corporate actions tied to its Nasdaq-listed common shares.
Milestone Pharmaceuticals (MIST) enrolled its first European participant in ReVeRA-301, the Phase 3 trial evaluating etripamil nasal spray for AFib-RVR.
The participant enrolled through the Dutch Cardiovascular Investigator Network in the Netherlands. U.S. enrollment began in August 2026 and has expanded to Canada. The randomized, double-blind, placebo-controlled study targets approximately 150 treated patient events involving atrial fibrillation with rapid ventricular rate, or AFib-RVR. Patients will self-administer a 70 mg repeat-dose regimen in medically unsupervised settings. The primary endpoint is reduction in ventricular rate within 30 minutes; a key secondary endpoint measures patient-reported symptom improvement.
Milestone is pursuing a single-study supplemental new drug application pathway for AFib-RVR based on safety data to date. The regimen is already FDA-approved as CARDAMYST for PSVT, a different fast-heartbeat condition.
Milestone Pharmaceuticals (MIST) enrolled the first Canadian participant in its ReVeRA-301 Phase 3 trial at the Montreal Heart Institute.
The institute is the study’s first Canadian site. Enrollment there follows the first participant enrolled in the United States. The multinational, randomized, double-blind, placebo-controlled trial targets approximately 150 treated events of atrial fibrillation with rapid ventricular rate (AFib-RVR). Participants experiencing symptoms will self-administer etripamil nasal spray outside medical supervision using a 70 mg repeat-dose regimen. The primary endpoint is reduction in ventricular rate within 30 minutes; a secondary endpoint measures patient-reported symptom improvement.
The same regimen is FDA-approved as CARDAMYST for paroxysmal supraventricular tachycardia in adults, a different condition. Etripamil remains under study for AFib-RVR. In a Phase 2 emergency-room study, a single 70 mg dose reduced ventricular rate and improved symptom relief and treatment satisfaction.
Milestone Pharmaceuticals (MIST) received approval from China’s National Medical Products Administration (NMPA) for etripamil nasal spray to treat paroxysmal supraventricular tachycardia (PSVT) in adults in China, marking the first regulatory approval of etripamil outside the United States.
The decision triggers a $2.0 million milestone payment to Milestone. Everest Medicines holds exclusive rights to develop and commercialize etripamil in Greater China and, under the license, Milestone is eligible for up to $98.0 million in additional commercial and development milestones plus tiered royalties of up to 18% on future sales. Approval is supported by the global Phase 3 RAPID study and China Phase 3 JX02002 trial, where etripamil was significantly superior to placebo in converting PSVT to sinus rhythm within 30 minutes (hazard ratio 3.002; p=0.0005), with comparable adverse events to placebo and no serious adverse events within 24 hours of dosing across Phase 3 studies.
Milestone Pharmaceuticals (MIST)/b) will participate in three upcoming healthcare investor conferences in September 2026, featuring fireside chats and 1x1 meetings.Management presents at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 8 at 1:30 pm ET, and at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 15 at 10:30 am ET. Milestone will also hold 1x1 meetings at the Cantor Global Healthcare Conference in New York on September 10. Webcasts for applicable presentations will be accessible for about 90 days via the company’s website.
Milestone Pharmaceuticals (Nasdaq: MIST) reported results from a 247‑patient longitudinal web-based survey on paroxysmal supraventricular tachycardia (PSVT), presented at the ESC Congress 2026. The study evaluated how PSVT affects daily life and quality of life between episodes in adults in the United States and United Kingdom.
According to Milestone, about two-thirds of patients changed their lifestyle to avoid stress and nearly 40% reduced activity or exercise. Seventy‑three percent reported daytime activity interruption, with driving (53%) and travel (43%) commonly avoided and rated as particularly bothersome. Persistent anxiety, burdensome medication side effects, and dissatisfaction with sleep (30%) and work capacity (22%) highlight substantial quality‑of‑life impact and an unmet treatment need.
Milestone Pharmaceuticals (Nasdaq: MIST) has enrolled the first patient in ReVeRA-301, a pivotal Phase 3, multinational, randomized, double-blind, placebo-controlled trial of etripamil nasal spray for atrial fibrillation with rapid ventricular rate (AFib-RVR). The study will include approximately 150 patients.
Prompted by symptoms, patients will self-administer the same 70 mg repeat-dose regimen of etripamil that is FDA approved for paroxysmal supraventricular tachycardia (PSVT) as CARDAMYST. The primary endpoint is ventricular rate reduction within 30 minutes, with a key secondary endpoint of symptom improvement. Milestone is pursuing a single-study sNDA pathway for AFib-RVR based on prior Phase 2 data showing reduced ventricular rate and improved symptom relief and treatment satisfaction.
Milestone Pharmaceuticals (Nasdaq: MIST) reported second quarter 2026 results and launch progress for CARDAMYST nasal spray for PSVT. More than 800 unique prescribers and over 1,500 scripts for >1,300 patients were recorded through June 30, up from ~200 prescribers and 300 scripts at Q1-end.
Commercial coverage for CARDAMYST expanded from ~25% of U.S. commercially insured lives during Q2 to over 50% to date, supported by new formulary decisions from major insurers. The Phase 3 ReVeRA-301 registrational trial in AFib-RVR is open with sites activated, targeting first patient enrollment in H2 2026. Regulatory review for etripamil in PSVT continues in Europe (EMA decision expected H1 2027) and China.
Cash, cash equivalents and short-term investments totaled $170.6 million as of June 30, 2026, versus $106.0 million at year-end 2025, with runway into H2 2027. Q2 2026 product revenue was $0.6 million, R&D expenses declined modestly year over year, and net loss widened to $28.6 million.
Milestone Pharmaceuticals (Nasdaq: MIST) will report its second quarter 2026 financial results, for the period ended June 30, 2026, on Wednesday, August 12, 2026, before the market opens. The company will host an investor conference call and webcast at 8:30am ET, with replay available via its website.
Milestone Pharmaceuticals (Nasdaq:MIST) granted a total of 288,000 stock options under its 2021 Inducement Plan as a material inducement for hiring six new employees, in line with Nasdaq Listing Rule 5635(c)(4).
The options, dated July 1, 2026, have a $1.32 exercise price and four-year vesting.
Alpha Cognition (Nasdaq: ACOG) elected Dr. Robert Wills as Chairman of the Board, succeeding retiring chair Len Mertz.
Dr. Wills has served on the board since 2025 and holds leadership roles at several biopharma companies, as Alpha Cognition advances ZUNVEYL’s commercial launch and its neurodegenerative pipeline.